Loading
Zonghai Li moved CAR-T therapy from blood cancers into stomach cancer, founding CARsgen and developing satri-cel, the first CAR-T approved for a solid tumour.
At the Shanghai Cancer Institute Li developed GPC3-directed CAR-T for liver cancer and the Claudin 18.2 CAR-T CT041, whose phase 1 results (Nature Medicine 2022) and randomised phase 2 trial in gastric cancer led to NMPA approval as satricabtagene autoleucel in 2025; CARsgen's fully human BCMA CAR-T zevorcabtagene autoleucel was approved in 2024. He founded CARsgen in 2014 and listed it in Hong Kong in 2021.
| Title | Journal | Year |
|---|---|---|
| Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results | Nature Medicine | 2022 |
Shares Zevorcabtagene autoleucel, CARsgen Therapeutics, BCMA, CAR-T cell therapy and the tag china.
Shares CARsgen Therapeutics, Satricabtagene autoleucel, Claudin 18.2, CAR-T cell therapy and the tag china.
Shares CARsgen Therapeutics, Satricabtagene autoleucel, Claudin 18.2, CAR-T cell therapy and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tag china.
Shares Gastric & gastro-oesophageal junction cancer and the tag china.
Shares CAR-T cell therapy and the tag china.